These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.
    Author: Barry AL, Aldridge KE, Allen SD, Fuchs PC, Gerlach EH, Jones RN, Pfaller MA.
    Journal: Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):794-8. PubMed ID: 3145868.
    Abstract:
    Six geographically separate laboratories within the USA tested 6,198 bacterial isolates against FCE 22101 (a penem), imipenem (a carbapenem) and ceftazidime (a third-generation cephalosporin). Ninety-three percent of 2,749 Enterobacteriaceae were inhibited by FCE 22101, while 95% were susceptible to ceftazidime and 99% were susceptible to imipenem. FCE 22101 had little activity against Pseudomonas spp. but was active against most gram-positive pathogens, including enterococci. FCE 22101 MICs for standard quality control strains were defined as 0.5-2.0 micrograms/ml for Escherichia coli ATCC 25922, 2-8 micrograms/ml for Enterococcus faecalis ATCC 29212 and 0.06-0.25 microgram/ml for Staphylococcus aureus ATCC 29213.
    [Abstract] [Full Text] [Related] [New Search]